Kizaki | Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia | Buch | 978-4-431-56255-9 | sack.de

Buch, Englisch, 193 Seiten, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 3168 g

Kizaki

Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia


Softcover Nachdruck of the original 1. Auflage 2016
ISBN: 978-4-431-56255-9
Verlag: Springer

Buch, Englisch, 193 Seiten, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 3168 g

ISBN: 978-4-431-56255-9
Verlag: Springer


Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML.

Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.

Kizaki Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia jetzt bestellen!

Zielgruppe


Professional/practitioner


Autoren/Hrsg.


Weitere Infos & Material


1. Identification and Biology of CML Stem Cells.- 2. Molecular Mechanisms of CML Stem Cell Maintenance.- 3. Roles for Signaling Molecules in the Growth and Survival of CML Cells.- 4. Goal of CML Treatment in the Tyrosine Kinase Inhibitor Era.- 5. Biomarkers for Determining the Prognosis of CML.- 6. Updated European Leukemia Net Recommendations for the Management of CML.- 7. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis.- 8. Recommendations for Management of CML in the Era of Second-Generation TKIs.- 9. Role of New TKIs and Combinations with Interferon-a for the Treatment of CML.- 10. Safety Profiles of First-Line TKIs and Managing Adverse Effects.- 11. Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance.- 12. Discontinuation of Therapy and Treatment-Free Remission in CML.


Professor and Chairman of Department of Hematology in Saitama Medical Center, Saitama Medical University.



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.